The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 2, 2003, Pages 363-371

  Cook, Charles D ^a   Beardsley, Patrick M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

BP897; Dopamine agonist; Dopamine antagonist; Locomotor activity; Mice; Mu opioid

Indexed keywords

BP 897; CAFFEINE; CENTRAL STIMULANT AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE-D3 RECEPTOR; ETICLOPRIDE; MORPHINE; MU OPIATE RECEPTOR; NAFADOTRIDE; NAPHTHALENE DERIVATIVE; NARCOTIC AGENT; NARCOTIC ANTAGONIST; PYRROLIDINE DERIVATIVE; QUINELORANE; QUINOLINE DERIVATIVE; QUINPIROLE; SALICYLAMIDE DERIVATIVE; WATER;

ANIMAL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SPECIFICITY; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

EID: 0038107684     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00090-X     Document Type: Article

References (56)

1. Acquas E., Tanda G., Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology. 27:2002;182-193.
2. Audinot V., Newman-Tancredi A., Gobert A., Rivet J.M., Brocco M., Lejeune F.et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J. Pharmacol. Exp. Ther. 287:1998;187-197.
3. Brase D.A., Loh H.H., Way E.L. Comparison of the effects of morphine on locomotor activity, analgesia and primary and protracted physical dependence in six mouse strains. J. Pharmacol. Exp. Ther. 201:1977;368-374.
4. 2-like dopamine receptors in the locomotor stimulant effects of cocaine alone in mice. Psychopharmacology. 155:2001;69-77.
5. Chio C.L., Lajiness M.E., Huff R.M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 45:1994;51-60.
6. Colpaert F.C., Niemegeers J.E., Janssen P.A. Differential haloperidol effect on two indices of fentanyl-saline discrimination. Psychopharmacology. 53:1977;169-173.
7. Cook C.D., Beardsley P.M. Effects of dopamine D3/2 drugs on the discriminative stimulus effects of mu opioids in heroin-trained rats. Drug Alcohol Depend. 63:2001;S31.
8. Cook C.D., Picker M.J. Dopaminergic activity and the discriminative stimulus effects of mu opioids in pigeons: importance of training dose and attenuation by the D3 agonist (±)-7-OH-DPAT. Psychopharmacology. 136:1998;59-69.
9. Cook C.D., Rodefer J.S., Picker M.J. Selective attenuation of the antinociceptive effects of mu opioid by the putative dopamine D3 agonist 7-OH-DPAT. Psychopharmacology. 144:1999;239-247.
10. Cook C.D., Barrett A.C., Syvanthong C., Picker M.J. Modulatory effects of dopamine D3/2 agonists on kappa opioid-induced antinociception and diuresis in the rat. Psychopharmacology. 152:2000;14-23.
11. Corrigall W.A., Coen K.M. Selective D 1 and D 2 dopamine antagonists decrease response rates of food-maintained behavior and reduce the discriminative stimulus produced by heroin. Pharmacol. Biochem. Behav. 35:1990;351-355.
12. Cory-Slechta D.A., Zuch C.L., Fox R.A.V. Comparison of a pre- vs. a putative postsynaptic dose of quinpirole. Pharmacol. Biochem. Behav. 55:1996;423-433.
13. Daly J.W., Bruns R.F., Snyder S.H. Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci. 28:1981;2083-2097.
14. David V., Durkin T.P., Cazala P. Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens. Psychopharmacology. 160:2002;307-317.
15. Depoortere R., Perrault G., Sanger D.J. Behavioral effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology. 124:1996;231-240.
16. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1988;1067-1080.
17. Estler C.J. Influence of pimozide on the locomotor hyperactivity produced by caffeine. J. Pharm. Pharmacol. 31:1979;126-127.
18. Fujiwara H. Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice. Pharmacol. Biochem. Behav. 41:1992;301-308.
19. Garrett B.E., Griffiths R.R. The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol. Biochem. Behav. 57:1997;533-541.
20. Garrett B.E., Holtzman S.G. D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol. Biochem. Behav. 47:1994;89-94.
21. Gerrits M., Ramsey N.F., Wolterink G., van Ree J.M. Lack of evidence for an involvement of nucleus accumbens dopamine D1 receptors in the initiation of heroin self-administration in the rat. Psychopharmacology. 114:1994;486-494.
22. Gilliland S.L., Alper R.H., Levant B. Pharmacology of quinpirole-stimulated [35S]GTPgammaS binding: discrepancy with receptor binding profile. Eur. J. Pharmacol. 392:2000;125-128.
23. Hemby S.E., Smith J.E., Dworkin S.I. The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats. J. Pharmacol. Exp. Ther. 277:1996;1247-1258.
24. Joyce E.M., Koob G.F. Amphetamine-, scopolamine- and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine system. Psychopharmacology. 73:1981;311-313.
25. Kamei J., Saitoh A. Modification of the effects of 7-OH-DPAT, a dopamine D3-receptor agonist, on morphine-induced hyperlocomotion by diabetes. Life Sci. 59:1996;773-780.
26. Kaplan G.B., Greenblatt D.J., Kent M.A., Cotreau M.M., Arcelin G., Shader R.I. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology. 6:1992;145-153.
27. Koeltzow T.E., Xu M., Cooper D.C., Hu X.-T., Tonegawa S., Wolf M.E.et al. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
28. Kuribara H. Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur. J. Pharmacol. 275:1995;251-258.
29. Kuschinsky K., Hornykiewicz O. Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur. J. Pharmacol. 26:1974;41-50.
30. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49:1997;231-252.
31. 2 dopamine receptors by nafadotride. Neuropsychopharmacology. 17:1997;67-71.
32. Levant B., Moehlenkamp J.D., Morgan K.A., Leonard N.L., Cheng C.C. Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. J. Pharmacol. Exp. Ther. 278:1996;145-153.
33. Logan L., Seale T.W., Carney J.M. Inherent differences in sensitivity to methylxanthines among inbred mice. Pharmacol. Biochem. Behav. 24:1986;1281-1286.
34. Longoni R., Spina L., Di Chiara G. Dopaminergic D-1 receptors: essential role in morphine-induced hypermotility. Psychopharmacology. 93:1987;401-402.
35. Manzanedo C., Aguilar M.A., Minarro J. The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice. Psychopharmacology. 143:1999;82-88.
36. McCarten M.D., Lal H. Attenuation of the discriminative stimulus strength of morphine by haloperidol. Neuropharmacology. 18:1979;465-467.
37. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G.et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 400:1999;371-375.
38. Robertson G.S., Tham C.S., Wilson C., Jakubovic A., Fibiger H.C. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J. Pharmacol. Exp. Ther. 264:1993;1344-1351.
39. Rodriguez-Arias M., Broseta I., Aguilar M.A., Minarro J. Lack of specific effects of selective D(1) and D(2) dopamine antagonists vs. risperidone on morphine-induced hyperactivity. Pharmacol. Biochem. Behav. 66:2000;189-197.
40. Sautel F., Griffon N., Levesque D., Pilon C., Schwartz J.C., Sokoloff P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. NeuroReport. 6:1995;329-332.
41. See R.E., Sorg B.A., Chapman M.A., Kalivas P.W. In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists. Neuropharmacology. 30:1991;1269-1274.
42. Shippenberg T.S., Herz A. Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur. J. Pharmacol. 151:1988;233-242.
43. Shippenberg T.S., Bals-Kubik R., Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 265:1993;53-59.
44. Snyder S.H., Katims J.J., Annau A., Bruns R.F., Daly J.W. Adenosine receptors and the behavioral effects of methylxanthines. Proc. Natl. Acad. Sci. U. S. A. 78:1981;3260-3264.
45. Suzuki T., Maeda J., Funada M., Misawa M. The D3-receptor agonist (±)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. Neurosci. Lett. 187:1995;45-48.
46. Swerdlow N.R., Koob G.F. Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat. Pharmacol. Biochem. Behav. 23:1985;303-307.
47. Timmerman W., De Vries J.B., Westerink B.H. Effects of D-2 agonists on the release of dopamine: localization of the mechanism of action. Naunyn Schmiedebergs Arch. Pharmacol. 342:1990;650-654.
48. Ukai M., Hiraiwa E., Kameyama T. Pentazocine-like discriminative stimulus effects of morphine are blocked by the dopamine D-1 antagonist SCH 23390, but not by the dopamine D-2 antagonist sulpiride. Brain Res. 541:1991;146-148.
49. Vaccarino F.J., Amalric M., Swerdlow N.R., Koob G.F. Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in the rat. Pharmacol. Biochem. Behav. 24:1986;61-65.
50. White B.C., Simpson C.C., Adams J.E., Harkins D. Jr. Monoamine synthesis and caffeine-induced locomotor activity. Neuropharmacology. 17:1978;511-513.
51. Wicke K., Garcia-Ladona J. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur. J. Pharmacol. 424:2001;85-90.
52. Winger G., France C.P., Woods J.H., Smith C.B., Medzihradsky F., Iorio M.A. Opioid and non-opioid effects of novel butyrophenone analogues. Neuropsychopharmacology. 7:1992;177-187.
53. Wise R.A., Leone P., Rivest R., Leeb K. Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse. 21:1995;140-148.
54. Wood P.L., McQuade P., Richard J.W., Thakur M. Agonist/antagonist analgesics and nigrostiatal dopamine metabolism in the rat: evidence of receptor dualism. Life Sci. 33:1983;759-762.
55. Wood M.D., Boyfield I., Nash D.J., Jewitt F.R., Avenell K.Y., Riley G.J. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur. J. Pharmacol. 407:2000;47-51.
56. Zarrindast M.R., Zarghi A. Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible D-1 and D-2 receptor involvement. Gen. Pharmacol. 23:1992;1221-1225.